AbbVie Inc. (ABBV) Gross Margin: 70.68%
Is AbbVie Inc.’s gross margin high or low?
AbbVie Inc.'s gross margin of 70.68% is in line with its 5-year average of 68.00%, near the high end of its 5-year range (62.42%–70.24%).
The gross margin for AbbVie Inc. (ABBV) is 70.68% as of Wednesday, June 10, 2026. It is above its 12-month average by 0.81% (70.11%).
ABBV Gross Margin Chart
ABBV Average Gross Margin Chart
ABBV Current vs Average Gross Margin Chart
ABBV Gross Margin Metrics
GROSS MARGIN
70.68%
GROSS MARGIN AVG TTM
70.11%
GROSS MARGIN AVG 3Y
68.16%
GROSS MARGIN AVG 5Y
68.00%
GROSS MARGIN AVG 10Y
72.25%
GROSS MARGIN AVG 15Y
73.10%
GROSS MARGIN AVG 20Y
73.00%
CURRENT VS TTM AVG
+0.81%
CURRENT VS 3Y AVG
+3.69%
CURRENT VS 5Y AVG
+3.94%
CURRENT VS 10Y AVG
-2.17%
CURRENT VS 15Y AVG
-3.31%
CURRENT VS 20Y AVG
-3.18%
ABBV Competitors' Gross Margin
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| AbbVie Inc. (ABBV) | — | 70.68% | 70.11% | 68.16% | 68.00% |
| UnitedHealth Group Incorporated (UNH) | $368.44B | 18.80% | 20.43% | 22.48% | 23.36% |
| Merck & Co., Inc. (MRK) | $293.02B | 75.91% | 74.15% | 73.03% | 71.89% |
| Johnson & Johnson (JNJ) | $574.15B | 69.12% | 70.92% | 69.98% | 69.30% |
| Amgen Inc. (AMGN) | $183.75B | 71.46% | 66.16% | 69.53% | 71.51% |
| Thermo Fisher Scientific Inc. (TMO) | $179.45B | 39.41% | 39.50% | 40.36% | 43.54% |
| Abbott Laboratories (ABT) | $154.66B | 56.38% | 53.17% | 51.86% | 51.92% |
| Gilead Sciences, Inc. (GILD) | $151.21B | 79.35% | 78.55% | 78.10% | 78.28% |
| Intuitive Surgical, Inc. (ISRG) | $146.44B | 66.29% | 66.73% | 66.82% | 67.04% |
| Pfizer Inc. (PFE) | $146.36B | 69.35% | 68.05% | 62.23% | 63.06% |
Gross Margin Analysis
Gross Margin
70.7%
(Revenue - COGS) / Revenue
AbbVie Inc. Gross Margin Formula & Definition
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
AbbVie Inc. Gross Margin FAQ
- What is the gross margin for AbbVie Inc. (ABBV)?
- The gross margin for ABBV stock is 70.68%.
- Is AbbVie Inc.'s gross margin high or low?
- AbbVie Inc.'s gross margin of 70.68% is in line with its 5-year average of 68.00%, near the high end of its 5-year range (62.42%–70.24%).
- What is the TTM average gross margin for AbbVie Inc. (ABBV)?
- The TTM average gross margin for ABBV stock is 70.11%.
- What is the 3Y average gross margin for AbbVie Inc. (ABBV)?
- The 3Y average gross margin for ABBV stock is 68.16%.
- What is the 5Y average gross margin for AbbVie Inc. (ABBV)?
- The 5Y average gross margin for ABBV stock is 68.00%.
- What is the 10Y average gross margin for AbbVie Inc. (ABBV)?
- The 10Y average gross margin for ABBV stock is 72.25%.
- What is the 15Y average gross margin for AbbVie Inc. (ABBV)?
- The 15Y average gross margin for ABBV stock is 73.10%.
- What is the 20Y average gross margin for AbbVie Inc. (ABBV)?
- The 20Y average gross margin for ABBV stock is 73.00%.
AbbVie Inc. Gross Margin History
| DATE | GROSS MARGIN |
|---|---|
| 2025-12-31 | 70.24% |
| 2024-12-31 | 69.99% |
| 2023-12-31 | 62.42% |
| 2022-12-31 | 70.00% |
| 2021-12-31 | 68.96% |
| 2020-12-31 | 66.41% |
| 2019-12-31 | 77.64% |
| 2018-12-31 | 76.44% |
| 2017-12-31 | 75.05% |
| 2016-12-31 | 77.25% |
| 2015-12-31 | 80.31% |
| 2014-12-31 | 77.83% |
| 2013-12-31 | 75.62% |
| 2012-12-31 | 75.47% |
| 2011-12-31 | 73.41% |
| 2010-12-31 | 72.55% |
| 2009-12-31 | 71.46% |
Related Metrics
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Michael